Half-year report · Q2
4883.TEDINET S100WJ2W
Period2025-01-01 → 2025-06-30
Filed2025-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 41
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Operating income | −¥1.0bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | −¥839m | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.0bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥780m | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.0bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥780m | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.0bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥781m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.0bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | −¥781m | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥3.4bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥1.4bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥229m | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥143m | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥3.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.6bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥910m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥931m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥583,000 | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥188,000 | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥188,000 | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥658m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥256m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-13.78 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.57 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.98 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 92.5% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.5% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 368
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding research and development expenses (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Major components of other income bnk (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | Prior1YTDDuration | Original text (Japanese)当社グループは、遺伝子治療薬開発事業の単一セグメントであり重要性が乏しいため、セグメント情報の記載は省略しております。 | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration | Original text (Japanese)当社グループは、遺伝子治療薬開発事業の単一セグメントであり重要性が乏しいため、セグメント情報の記載は省略しております。 | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |